1. Home
  2. GILD
  3. GILD News

Latest Gilead Sciences Inc. (GILD) News on November 19, 2024

GILD

MT Newswires

21 hours ago

Daiwa Securities Adjusts Gilead Sciences Price Target to $90 From $73

GILD

MT Newswires

21 hours ago

RBC Capital Adjusts Gilead Sciences Price Target to $84 From $81

Gilead’s Livdelzi shows promise in PBC clinical trial
GILD

Clinical Trials Arena

a day ago

Gilead’s Livdelzi shows promise in PBC clinical trial

GILD

Morningstar Research

a day ago

Analyst Report: Gilead Sciences, Inc.

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
GILD

Benzinga

4 days ago

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease

GILD

MT Newswires

4 days ago

Gilead Sciences Says Most of Phase 3 Primary Biliary Cholangitis Participants Treated With Livdelzi Achieved Biochemical Response

Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
GILD

Business Wire

4 days ago

Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

GILD

MT Newswires

4 days ago

Wolfe Research Initiates Gilead Sciences at Outperform With $110 Price Target

GILD

Investing.com

5 days ago

Citi initiates coverage on 5 new biotech stocks

Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
GILD

Zacks

5 days ago

Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
GILD

Zacks

5 days ago

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

GILD

MT Newswires

5 days ago

Gilead Sciences Prices $3.5 Billion Senior Notes Offering

Gilead Prices $3.5 Billion of Senior Unsecured Notes
GILD

Business Wire

5 days ago

Gilead Prices $3.5 Billion of Senior Unsecured Notes

Gilead Sciences' (NASDAQ:GILD) Soft Earnings Are Actually Better Than They Appear
GILD

Simply Wall St.

6 days ago

Gilead Sciences' (NASDAQ:GILD) Soft Earnings Are Actually Better Than They Appear

GILD

MT Newswires

6 days ago

Gilead Sciences Says Investigational HIV Prevention Drug Showed High Infection Reduction

Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
GILD

Business Wire

6 days ago

Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
GILD

GuruFocus.com

6 days ago

Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight

GILD or VRTX: Which Is the Better Value Stock Right Now?
GILD

Zacks

7 days ago

GILD or VRTX: Which Is the Better Value Stock Right Now?

Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
GILD

Business Wire

7 days ago

Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

3 Spectacular High-Yield Dividend Stocks to Buy in November
GILD

Motley Fool

9 days ago

3 Spectacular High-Yield Dividend Stocks to Buy in November

Gilead Sciences to Present at Upcoming Investor Engagements
GILD

Business Wire

11 days ago

Gilead Sciences to Present at Upcoming Investor Engagements

GILD

Morningstar Research

11 days ago

Analyst Report: Gilead Sciences, Inc.

GILD

MT Newswires

11 days ago

Maxim Downgrades Gilead Sciences to Hold From Buy

Gilead Sciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GILD

Simply Wall St.

11 days ago

Gilead Sciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

GILD

MT Newswires

11 days ago

Truist Securities Raises Price Target on Gilead Sciences to $97 From $83, Maintains Hold Rating

Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise
GILD

Investor's Business Daily

12 days ago

Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise

HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
GILD

Benzinga

12 days ago

HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook

Gilead increases 2024 outlook, expects new drug filing by end of year
GILD

Yahoo Finance

12 days ago

Gilead increases 2024 outlook, expects new drug filing by end of year

GILD

MT Newswires

12 days ago

Raymond James Adjusts Gilead Sciences Price Target to $103 From $95, Maintains Outperform Rating

Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook
GILD

Zacks

12 days ago

Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook

Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
GILD

Business Wire

12 days ago

Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic

GILD

MT Newswires

12 days ago

JPMorgan Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Overweight Rating

GILD

MT Newswires

12 days ago

Barclays Adjusts Price Target on Gilead Sciences to $95 From $84, Maintains Equalweight Rating

GILD

MT Newswires

12 days ago

TD Cowen Adjusts Price Target on Gilead Sciences to $95 From $85, Maintains Buy Rating

GILD

MT Newswires

12 days ago

BMO Capital Adjusts Price Target on Gilead Sciences to $102 From $94, Maintains Outperform Rating

GILD

MT Newswires

12 days ago

Oppenheimer Adjusts Price Target on Gilead Sciences to $105 From $95, Maintains Outperform Rating

GILD

MT Newswires

12 days ago

Piper Sandler Adjusts Price Target on Gilead Sciences to $105 From $95, Maintains Overweight Rating

GILD

MT Newswires

12 days ago

Wells Fargo Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Overweight Rating

Gilead Sciences Inc (GILD) Q3 2024 Earnings Call Highlights: Strong HIV and Oncology Sales ...
GILD

GuruFocus.com

12 days ago

Gilead Sciences Inc (GILD) Q3 2024 Earnings Call Highlights: Strong HIV and Oncology Sales ...

Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript
GILD

Motley Fool

12 days ago

Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript

Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say
GILD

Zacks

13 days ago

Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say

Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
GILD

Zacks

13 days ago

Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates

Gilead Sciences Rides Covid Treatment To Another Beat And Raise
GILD

Investor's Business Daily

13 days ago

Gilead Sciences Rides Covid Treatment To Another Beat And Raise

GILD

MT Newswires

13 days ago

Gilead Sciences Q3 Non-GAAP EPS Declines, Revenue Increases

Gilead 3rd-quarter results beat Wall Street estimates, raises outlook
GILD

Reuters

13 days ago

Gilead 3rd-quarter results beat Wall Street estimates, raises outlook

GILD

Associated Press Finance

13 days ago

Gilead: Q3 Earnings Snapshot

Gilead Sciences Announces Third Quarter 2024 Financial Results
GILD

Business Wire

13 days ago

Gilead Sciences Announces Third Quarter 2024 Financial Results

Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy Sales
GILD

Investor's Business Daily

13 days ago

Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy Sales

Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals
GILD

Pharmaceutical Technology

13 days ago

Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals

GILD

Morningstar Research

14 days ago

Analyst Report: Gilead Sciences, Inc.

Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
GILD

Business Wire

14 days ago

Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World

Is Gilead Sciences, Inc. (GILD) the Best Pharma Stock to Buy Right Now?
GILD

Insider Monkey

15 days ago

Is Gilead Sciences, Inc. (GILD) the Best Pharma Stock to Buy Right Now?

Gilead Science to Report Q3 Earnings: What's in the Cards?
GILD

Zacks

15 days ago

Gilead Science to Report Q3 Earnings: What's in the Cards?

GILD

MT Newswires

15 days ago

Jefferies Adjusts Gilead Sciences Price Target to $105 From $95

Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
GILD

Zacks

18 days ago

Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
GILD

Zacks

19 days ago

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
GILD

Zacks

19 days ago

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

GILD

ACCESSWIRE

19 days ago

AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies

Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline
GILD

Zacks

20 days ago

Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline

Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
GILD

Zacks

21 days ago

Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why

3 Absurdly Cheap Stocks That Pay High Dividends
GILD

Motley Fool

a month ago

3 Absurdly Cheap Stocks That Pay High Dividends

Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
GILD

Zacks

a month ago

Why Gilead Sciences (GILD) Dipped More Than Broader Market Today

Gilead and MSD to advance once-weekly HIV treatment to Phase III
GILD

Clinical Trials Arena

a month ago

Gilead and MSD to advance once-weekly HIV treatment to Phase III

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
GILD

Business Wire

a month ago

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

Gilead, MRK Report Data From Investigational Combination Study for HIV
GILD

Zacks

a month ago

Gilead, MRK Report Data From Investigational Combination Study for HIV

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
GILD

Benzinga

a month ago

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks

GILD

MT Newswires

a month ago

Gilead Sciences, Merck Say Phase 2 Study for HIV Treatment Combination Meets New Endpoints

GILD

MT Newswires

a month ago

Leerink Partners Upgrades Gilead Sciences to Outperform, Price Target is $96

GILD

MT Newswires

a month ago

Leerink Partners Upgrades Gilead Sciences to Outperform From Market Perform, Price Target is $96

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
GILD

Business Wire

a month ago

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE
GILD

Insider Monkey

a month ago

Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE

After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
GILD

Benzinga

a month ago

After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment

GILD

MT Newswires

a month ago

Gilead Sciences to Withdraw US Accelerated Approval for Trodelvy in Bladder Cancer

Gilead withdraws bladder cancer drug in US after failed trial
GILD

Reuters

a month ago

Gilead withdraws bladder cancer drug in US after failed trial

High Growth Tech Stocks to Watch in October 2024
GILD

Simply Wall St.

a month ago

High Growth Tech Stocks to Watch in October 2024

GILD

MT Newswires

a month ago

BMO Capital Adjusts Price Target on Gilead Sciences to $94 From $85

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
GILD

Zacks

a month ago

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
GILD

Zacks

a month ago

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

How Brookfield Infrastructure, Invitation Homes And Gilead Sciences Can Put Cash In Your Pocket
GILD

Benzinga

a month ago

How Brookfield Infrastructure, Invitation Homes And Gilead Sciences Can Put Cash In Your Pocket

Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
GILD

Zacks

a month ago

Gilead's HIV Prevention Treatment Lenacapavir Shows Potential

GILD

MT Newswires

a month ago

Morgan Stanley Adjusts Price Target on Gilead Sciences to $84 From $79

Is Gilead Sciences, Inc. (NASDAQ:GILD) The Most Popular Stock Among Mutual Funds According To Goldman Sachs?
GILD

Insider Monkey

a month ago

Is Gilead Sciences, Inc. (NASDAQ:GILD) The Most Popular Stock Among Mutual Funds According To Goldman Sachs?

Gilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ...
GILD

GuruFocus.com

a month ago

Gilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ...

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
GILD

Business Wire

a month ago

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

GILD

MT Newswires

a month ago

Raymond James Adjusts Gilead Sciences Price Target to $95 From $94

GILD

MT Newswires

a month ago

JPMorgan Adjusts Price Target on Gilead Sciences to $100 From $95, Maintains Overweight Rating

Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
GILD

Business Wire

a month ago

Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know
GILD

Zacks

a month ago

Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
GILD

Business Wire

a month ago

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference

GILD

MT Newswires

a month ago

Wells Fargo Upgrades Gilead Sciences to Overweight From Equalweight, Adjusts PT to $100 From $78

AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history
GILD

Pharmaceutical Technology

a month ago

AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history

Gilead Sciences' (NASDAQ:GILD) investors will be pleased with their favorable 62% return over the last five years
GILD

Simply Wall St.

a month ago

Gilead Sciences' (NASDAQ:GILD) investors will be pleased with their favorable 62% return over the last five years

Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
GILD

Zacks

a month ago

Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?

GILD

MT Newswires

2 months ago

Goldman Sachs Adjusts Price Target on Gilead Sciences to $74 From $71

GILD

MT Newswires

2 months ago

Barclays Adjusts Price Target on Gilead Sciences to $84 From $76, Maintains Equalweight Rating

GILD

MT Newswires

2 months ago

RBC Lifts Price Target on Gilead Sciences to $75 From $74, Keeps Sector Perform Rating

GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
GILD

Zacks

2 months ago

GILD Grants Right for HIV PrEP Candidate to Six Generic Companies

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
GILD

Zacks

2 months ago

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

GILD

MT Newswires

2 months ago

Redburn Atlantic Adjusts Price Target on Gilead Sciences to $123 From $119, Maintains Buy Rating

Gilead signs agreements to facilitate access to HIV prevention drug
GILD

Pharmaceutical Technology

2 months ago

Gilead signs agreements to facilitate access to HIV prevention drug

Share on Social Networks: